X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs GLENMARK PHARMA - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA GLENMARK PHARMA TORRENT PHARMA/
GLENMARK PHARMA
 
P/E (TTM) x 24.6 13.6 180.6% View Chart
P/BV x 6.0 3.8 157.9% View Chart
Dividend Yield % 3.3 0.3 995.7%  

Financials

 TORRENT PHARMA   GLENMARK PHARMA
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-16
GLENMARK PHARMA
Mar-16
TORRENT PHARMA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,7201,262 136.3%   
Low Rs1,134672 168.8%   
Sales per share (Unadj.) Rs394.5270.6 145.8%  
Earnings per share (Unadj.) Rs101.824.9 409.2%  
Cash flow per share (Unadj.) Rs116.334.4 338.0%  
Dividends per share (Unadj.) Rs40.002.00 2,000.0%  
Dividend yield (eoy) %2.80.2 1,355.2%  
Book value per share (Unadj.) Rs200.3151.3 132.3%  
Shares outstanding (eoy) m169.22282.16 60.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.63.6 101.2%   
Avg P/E ratio x14.038.9 36.1%  
P/CF ratio (eoy) x12.328.1 43.7%  
Price / Book Value ratio x7.16.4 111.5%  
Dividend payout %39.38.0 488.8%   
Avg Mkt Cap Rs m241,435272,778 88.5%   
No. of employees `00010.910.0 108.6%   
Total wages/salary Rs m8,55913,782 62.1%   
Avg. sales/employee Rs Th6,129.67,614.9 80.5%   
Avg. wages/employee Rs Th785.81,374.8 57.2%   
Avg. net profit/employee Rs Th1,581.3700.2 225.9%   
INCOME DATA
Net Sales Rs m66,76476,340 87.5%  
Other income Rs m2,156356 605.4%   
Total revenues Rs m68,92076,696 89.9%   
Gross profit Rs m27,20414,172 192.0%  
Depreciation Rs m2,4612,691 91.4%   
Interest Rs m1,8591,789 103.9%   
Profit before tax Rs m25,04110,048 249.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-1,4030-   
Tax Rs m6,4143,028 211.8%   
Profit after tax Rs m17,2247,019 245.4%  
Gross profit margin %40.718.6 219.5%  
Effective tax rate %25.630.1 85.0%   
Net profit margin %25.89.2 280.6%  
BALANCE SHEET DATA
Current assets Rs m46,62259,096 78.9%   
Current liabilities Rs m32,84340,018 82.1%   
Net working cap to sales %20.625.0 82.6%  
Current ratio x1.41.5 96.1%  
Inventory Days Days7475 99.0%  
Debtors Days Days79119 66.3%  
Net fixed assets Rs m39,02939,075 99.9%   
Share capital Rs m846282 299.9%   
"Free" reserves Rs m31,40030,281 103.7%   
Net worth Rs m33,89042,703 79.4%   
Long term debt Rs m18,63724,873 74.9%   
Total assets Rs m90,136111,026 81.2%  
Interest coverage x14.56.6 218.7%   
Debt to equity ratio x0.50.6 94.4%  
Sales to assets ratio x0.70.7 107.7%   
Return on assets %21.27.9 266.9%  
Return on equity %50.816.4 309.2%  
Return on capital %48.517.5 277.1%  
Exports to sales %43.343.3 100.1%   
Imports to sales %6.97.4 92.4%   
Exports (fob) Rs m28,93433,044 87.6%   
Imports (cif) Rs m4,5845,672 80.8%   
Fx inflow Rs m29,18536,945 79.0%   
Fx outflow Rs m6,02161,066 9.9%   
Net fx Rs m23,165-24,122 -96.0%   
CASH FLOW
From Operations Rs m27,1323,449 786.8%  
From Investments Rs m-7,014-8,802 79.7%  
From Financial Activity Rs m-14,3526,986 -205.4%  
Net Cashflow Rs m5,767934 617.5%  

Share Holding

Indian Promoters % 71.5 48.3 148.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 6.9 101.7%  
FIIs % 12.6 34.4 36.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 10.5 83.8%  
Shareholders   26,511 56,727 46.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   FRESENIUS KABI ONCO.  AJANTA PHARMA  ALEMBIC LTD  ALEMBIC PHARMA  ELDER PHARMA  

Compare TORRENT PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of Share Buybacks, GST Cess on Motor Vehicles, and Top Stocks in Focus Today(Pre-Open)

Indian share markets witnessed buying interest on Wednesday and finished their session in the green for the second straight session. Heavy buying was seen in realty stocks, metal stocks and bank stocks.

Related Views on News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Glenmark: High Costs hit the Bottom line (Quarterly Results Update - Detailed)

Nov 8, 2016

Glenmark has announced its 2QFY16 results. The company has reported 15.7% YoY growth in net sales and 3.5% YoY increase in net profits. Here is our analysis of the results.

Glenmark: Other Income Boosts Profit Growth (Quarterly Results Update - Detailed)

Sep 6, 2016

Glenmark has announced its 1QFY17 results. The company has reported 15.8% YoY growth in net sales and 24% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

Dear PM Modi, India is Already Land of Self-Employed, and It Ain't Working(Vivek Kaul's Diary)

Aug 21, 2017

Most Indians who cannot find jobs, look at becoming self-employed.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

Think Twice Before You Keep Money In A Savings Bank Account(Outside View)

Aug 22, 2017

Post demonetisation, a cut in bank savings deposits rates was in the offing.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Aug 23, 2017 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 5-YR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS